HeartBeam (NASDAQ:BEAT) Issues Quarterly Earnings Results

Posted by Francis Steltz on May 14th, 2026

HeartBeam (NASDAQ:BEAT – Get Free Report) issued its quarterly earnings results on Wednesday. The medical research company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.02, FiscalAI reports.

Here are the key takeaways from HeartBeam’s conference call:

HeartBeam said it has now established flagship commercial accounts in all four target geographies — New York City, Dallas, South Florida and Southern California — through partnerships with ClearCardio and Atelier Health, giving the company an initial foothold in its direct-pay market.
Management said the limited commercial launch is getting strong early physician reception, with clinicians viewing the product as a differentiated, medical-grade 12-lead ECG that can be used anytime, anywhere, rather than relying on traditional in-office or emergency department testing.
The ALIGN-ACS pilot study for heart-attack detection is enrolling ahead of schedule, and the company expects to complete enrollment by the end of Q3 2026, using the data to inform a future FDA pivotal study and potential indication expansion.
HeartBeam completed its first working prototype of the on-demand 12-lead patch and has begun a pilot ischemia study in Europe, while continuing partnership discussions for a $2 billion ambulatory monitoring market opportunity.
The company strengthened its balance sheet with an $11.5 million financing and ended the quarter with just over $2 million in cash; management said pro forma cash would be about $12.4 million and now expects full-year 2026 cash outflow below $16 million, better than prior guidance.

HeartBeam Stock Down 2.5%

Shares of NASDAQ:BEAT traded down $0.03 during trading on Thursday, hitting $0.99. The stock had a trading volume of 815,984 shares, compared to its average volume of 1,325,606. HeartBeam has a 12-month low of $0.54 and a 12-month high of $4.00. The stock has a market capitalization of $40.47 million, a price-to-earnings ratio of -1.59 and a beta of -0.86. The stock has a 50-day simple moving average of $1.12 and a two-hundred day simple moving average of $1.52.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. D. Boral Capital downgraded shares of HeartBeam from a “buy” rating to a “hold” rating in a research report on Monday, April 20th. HC Wainwright restated a “buy” rating and set a $5.50 price target on shares of HeartBeam in a research note on Monday, March 16th. Finally, B. Riley Financial started coverage on shares of HeartBeam in a research note on Tuesday, March 31st. They set a “buy” rating and a $4.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $4.80.

Get Our Latest Stock Analysis on BEAT

Insider Activity at HeartBeam

In other HeartBeam news, Director Willem Elfrink purchased 187,500 shares of the business’s stock in a transaction that occurred on Thursday, April 16th. The shares were bought at an average price of $0.80 per share, for a total transaction of $150,000.00. Following the acquisition, the director owned 538,667 shares in the company, valued at $430,933.60. This represents a 53.39% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Mark E. Strome bought 750,000 shares of HeartBeam stock in a transaction that occurred on Thursday, April 16th. The shares were acquired at an average cost of $0.80 per share, with a total value of $600,000.00. Following the acquisition, the director owned 3,650,000 shares of the company’s stock, valued at $2,920,000. The trade was a 25.86% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 1,118,750 shares of company stock worth $895,000 over the last quarter. Insiders own 18.04% of the company’s stock.

Institutional Trading of HeartBeam

Hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its position in HeartBeam by 4.1% during the fourth quarter. Geode Capital Management LLC now owns 305,740 shares of the medical research company’s stock valued at $734,000 after buying an additional 12,142 shares during the period. Kestra Private Wealth Services LLC boosted its stake in shares of HeartBeam by 23.4% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 175,989 shares of the medical research company’s stock worth $290,000 after acquiring an additional 33,344 shares in the last quarter. State Street Corp grew its position in shares of HeartBeam by 60.1% during the 4th quarter. State Street Corp now owns 125,473 shares of the medical research company’s stock valued at $301,000 after acquiring an additional 47,100 shares during the period. Raymond James Financial Inc. increased its stake in shares of HeartBeam by 212.5% in the 3rd quarter. Raymond James Financial Inc. now owns 88,050 shares of the medical research company’s stock valued at $145,000 after purchasing an additional 59,872 shares in the last quarter. Finally, Insigneo Advisory Services LLC purchased a new position in shares of HeartBeam in the 4th quarter valued at about $74,000. 7.77% of the stock is owned by hedge funds and other institutional investors.

About HeartBeam

(Get Free Report)

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.